For most of this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss key issues related to pharmacology and prescribing choices. At the end, the focus shifts to the guidelines’ overall benefits and some new kinds of education they call for.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
This conversation covers some of the other major drug development stories from the EASL Congress 2024, with special focus on denifenstat, ION-224 and TAK-227, plus a look at the SPECIAL study on bariatric surgery and cirrhosis.
This conversation focuses on the tirzepatide late-breaker at the EASL Congress 2024 and broadens into a discussion of the other “Twin-cretins,” all of which are GLP-glucagon combinations.
Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024.
EASL Secretary General Aleksander Krag and our other guests, Hannes Hagstrom and Michelle Long, join Jörn Schattenberg and Roger Green to discuss MASLD-related highlights of EASL Congress 2024.
The group, including co-hosts Louise Campbell and Roger Green along with guests Jeff McIntyre and Mike Betel, dives deeper into the care challenges and barriers confronting MASH patient care today.
The conversation shifts to look first at challenges caused by explosion in the use of incretin agonists like GLP-1s to treat obesity and diabetes and second by the opportunities creating by on-site scanning.
Patient advocates Jeff McIntyre (Global Liver Institute) and Mike Betel (Fatty Liver Alliance, Liver Action Network) join Louise Campbell and Roger Green to discuss GLI’s premier MASH patient event, now known as Global Fatty Livery Day.
Sven Francque and William Alazawi join the Surfers to to consider how we have translated the lessons of previous failed trials into better designs that produce successful trials.
